EriVan Bio is formed by a group of highly talented and experienced experts who have remarkable scientific backgrounds. The team also enjoys business and operational experience and expertise. Although the team is relatively small, it is very agile. Erivan Bio also has the pleasure to use a very special advisory board with long biotechnology industry experience and proven accomplishments.
Dr. Nasser Nassiri Koopaei, CEO
Dr. Nassiri Koopaei has more than 4 years of experience in the biopharmaceutical industry including R&D, manufacturing and business development. He has been involved in product development and launch and merges technical expertise with innovations and agility to turn a startup company into a successful business. He has co-authored multiple articles and books in pharmaceutical research and market analysis. Dr. Nassiri Koopaei holds a doctorate in pharmacy, a master’s in public health and a master’s in chemical and pharmaceutical engineering from the University of Tehran.
Darin Cook, Chairman of the Board
Darin Cook is the co-founder and co-CEO of Infinite Energy, a multi-state energy supplier founded in Florida in 1994. Since then, Infinite Energy has grown from its original two-man operation into one of the largest privately held companies in Florida, with more than 350 employees and $500 million in annual revenue. The company has been recognized several times as one of the best companies to work for in the state.
In addition to his active role within the company, Darin mentors entrepreneurial graduate students at the University of Florida. In 2004, the college named him Entrepreneur of the Year. In 2016, Infinite Energy was the Impact Winner by Business in the Greater Gainesville area. Also in 2016, Infinite Energy was the sole recipient of the University’s Pinnacle Award, which recognized the Gator-led business for making a significant impact through job creation, revenue generation, and innovation in its industry.
Prior to creating Infinite Energy, Darin was a natural gas buyer for Gainesville Regional Utilities and Florida Gas Utility. Darin is part of the Take Stock in Children program to help undeserved students obtain college scholarships. He also serves as a mentor for UF students at the Entrepreneurship & Innovation Center’s Veterans Entrepreneurship Program and the Poe Center for Business Ethics and Education Research. He is the chair of the Utility Advisory Board, a board member with the Gainesville Tech Council, a fellow at the Poe Center for Business Ethics and Education Research and an associate fellow with the Institute of Gainesville. Darin holds a Bachelor of Science degree in statistics from the University of Florida.
Dr. Gary McGill, Member of the Board
Professor McGill is the Director of the Fisher School of Accounting, an Associate Dean in the Warrington College of Business Administration, and holds the J. Roy Duggan Endowed Professorship in Accounting. Professor McGill is a CPA and spent several years in practice with Ernst & Whinney before earning his PhD at Texas Tech University and joining the faculty at the University of Florida in 1986. He held the PwC Endowed Professorship from 1999 to 2011.
He has published over 50 journal articles, book chapters, or research reports. He provided testimony to the Senate Finance Committee hearings on Enron in 2003, is the co-author of several books, and is the recipient of competitive research grants from Deloitte & Touche, Ernst & Young, Price Waterhouse, the AICPA, the Andrus Foundation, Fannie Mae's Housing Policy Research Division, the National Association of Realtors, and the National Homebuilder’s Association.
Professor McGill has served on the editorial boards of The Journal of the American Taxation Association and Advances in Taxation and as an Associate Editor of the Journal of Accounting Literature. Professor McGill has served on the boards of several professional organizations and is past President of the Federation of Schools of Accountancy. He has received numerous teaching awards at UF and he is a frequent lecturer on international tax, federal tax, and accounting for income taxes for academic, government, and professional organizations.
Dr. Thomas Schmittgen
Dr. Schmittgen is professor of pharmaceutics in the Department of Pharmaceutics in University of Florida. He assumed the role of Department Chair of Pharmaceutics in 2018. He is supported by the University of Florida’s Preeminence program with a focus on cancer therapeutics and drug discovery and development.
Dr. Schmittgen earned an undergraduate degree in pharmacy and graduate degrees in pharmaceutics from The Ohio State University and was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-95. He served on the faculty at Washington State University College of Pharmacy before returning to Ohio State in 2002. His research focuses on non-coding RNAs and cancer, with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 36,000 times and was recently ranked by the international journal Nature as the 21st most-cited scientific article of all time.
Dr. Schmittgen’s lab was the first to establish a link between altered microRNA expression in pancreatic cancer and the intellectual property resulting from this work is the basis of the product miRInform Pancreas™, a biomarker of early pancreatic cancer development. Recently, he has focused his attention on the development of extracellular vesicles as targeted drug delivery systems and therapeutic agents for the treatment of cancer.
Dr. Jeffrey Tate
Dr. Tate has more than 30 years of executive experience in the biopharmaceutical and nutritional supplements industries including drug manufacturing, intellectual property strategy, product development, and cGMP compliance. He retains deep knowledge of food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, and implementation of all aspects of regulatory compliance.
He has successfully established integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations in different companies. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.
Dr. Anthony Palmieri
Dr. Palmieri retired from the faculty at the University of Florida College of Pharmacy in the Department of Pharmaceutics. He has authored of over 80 publications and presentations on pharmaceutics, intellectual property, dosage forms, dissolution, pharmacy education and the history of pharmacy. He has interacted extensively with USAN and WHO to obtain non-proprietary names for Pharmacia and Upjohn. Dr. Palmieri is Past Chairman of the USAN Council and he is presently on the USAN review board. He has consulted as an expert witness on numerous litigations involving dose forms, excipients, bioequivalence, and dissolution. He is also an expert witness before the Office of Generic Drugs.
Dr. Palmieri has over twenty-five years of extensive and progressive responsibilities in an intellectual property management and technology transfer position, coupled with over fifteen years as a Professor of Pharmaceutics at major universities. Dr. Palmieri has successfully led projects across management lines where reporting relationships were often difficult to establish, no precedent existed, and the use of creative problem solving and communication skills were necessary.
Dr. Mahdi Aminian
Dr. Aminian is an Associate Professor in the Clinical Biochemistry Department at the Tehran University of Medical Sciences, Iran.
Dr. Aminian has extensive industrial experience in biopharmaceutical and vaccine industries in different roles, including design and scale up of a process for peroxidase production and animal toxin fractionation; much of his industrial experience was gained at the Razi Vaccine and Serum Research Institute from 2000 - 2007. He has extensive experience in product development, upstream and downstream process optimization and quality assurance.
Dr. Aminian's awards include Razi Best Lecture Award (2003), Young Investigator Award (2004), and the Hakim Jorjani Prize (2012).